Financial reports
10-K
2023 FY
Annual report
26 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
10-K
2022 FY
Annual report
16 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
24 Mar 22
10-Q
2021 Q3
Quarterly report
10 Nov 21
Current reports
8-K
Entry into a Material Definitive Agreement
25 Apr 24
8-K
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
22 Apr 24
8-K
Panbela Announces Transfer to OTCQB Market
17 Apr 24
8-K
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
26 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7 Mar 24
8-K
Regulation FD Disclosure
15 Feb 24
8-K
Departure of Directors or Certain Officers
13 Feb 24
8-K
Panbela Announces Closing of Approximately $9.0 Million Public Offering
1 Feb 24
8-K
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
29 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
25 Jan 24
Registration and prospectus
25-NSE
Exchange delisting
25 Apr 24
S-1
IPO registration
18 Apr 24
S-1
IPO registration
29 Mar 24
POS AM
Prospectus update (post-effective amendment)
29 Mar 24
424B4
Prospectus supplement with pricing info
30 Jan 24
S-1/A
IPO registration (amended)
25 Jan 24
S-1/A
IPO registration (amended)
25 Jan 24
S-1/A
IPO registration (amended)
22 Jan 24
S-8
Registration of securities for employees
5 Jan 24
D
Indefinite amount in equity / options, sold $2.00 mm, 2 investors
5 Jan 24
Proxies
PRER14A
Preliminary revised proxy
26 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
4 Apr 24
PRE 14A
Preliminary proxy
25 Mar 24
DEFA14A
Additional proxy soliciting materials
21 Dec 23
DEFA14A
Additional proxy soliciting materials
1 Dec 23
DEF 14A
Definitive proxy
24 Nov 23
PRE 14A
Preliminary proxy
14 Nov 23
DEFA14A
Additional proxy soliciting materials
3 Nov 23
DEF 14A
Definitive proxy
28 Apr 23
Other
EFFECT
Notice of effectiveness
17 Apr 24
EFFECT
Notice of effectiveness
3 Apr 24
EFFECT
Notice of effectiveness
29 Jan 24
CORRESP
Correspondence with SEC
25 Jan 24
CORRESP
Correspondence with SEC
25 Jan 24
CORRESP
Correspondence with SEC
22 Jan 24
UPLOAD
Letter from SEC
10 Jan 24
EFFECT
Notice of effectiveness
21 Dec 23
CORRESP
Correspondence with SEC
19 Dec 23
UPLOAD
Letter from SEC
28 Nov 23
Ownership
SC 13G/A
Lind Global Fund II LP
13 Feb 24
4
Change in insider ownership
13 Nov 23
3
Initial statement of insider ownership
13 Nov 23
4
Jeffrey E. Jacob
14 Sep 23
4
Jennifer K. Simpson
29 Mar 23
4
Susan Horvath
29 Mar 23
4
Michael T. Cullen
29 Mar 23
4
Daniel Donovan
29 Mar 23
4
Arthur Fratamico
29 Mar 23
4
Jeffrey E. Jacob
29 Mar 23